MR Spectroscopy Findings in Early Stages of Motor Neuron Disease

References

1. 1.↵
   1. Czaplinski A,
   2. Yen AA,
   3. Simpson EP,
   4. et al

   . Predictability of disease progression in amyotrophic lateral sclerosis. Muscle Nerve 2006;34:702–08

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Zoccolella S,
   2. Beghi E,
   3. Palagano G,
   4. et al

   . Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2008;79:33–37

   Abstract/FREE Full Text
3. 3.↵
   1. Chou SM,
   2. Norris FH

   . Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons. Muscle Nerve 1993;16:864–69

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Eisen A

   . Motor neuron disease: a primary disorder of corticomotoneurons? Muscle Nerve 1995;18:1080–81

   PubMedWeb of Science
5. 5.↵
   1. Pamphlett R,
   2. Kril J,
   3. Hng TM

   . Motor neuron disease: a primary disorder of corticomotoneurons? Muscle Nerve 1995;18:314–18

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Visser J,
   2. van den Berg-Vos RM,
   3. Franssen H,
   4. et al

   . Mimic syndromes in sporadic cases of progressive spinal muscular atrophy. Neurology 2002;58:1593–96

   Abstract/FREE Full Text
7. 7.↵
   1. Ince PG,
   2. Evans J,
   3. Knopp M,
   4. et al

   . Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60:1252–58

   Abstract/FREE Full Text
8. 8.↵
   1. Kim WK,
   2. Liu X,
   3. Sandner J,
   4. et al

   . Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009;73:1686–92

   Abstract/FREE Full Text
9. 9.↵
   1. Visser J,
   2. van den Berg-Vos RM,
   3. Franssen H,
   4. et al

   . Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 2007;64:522–28

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Gordon PH,
    2. Cheng B,
    3. Katz IB,
    4. et al

    . The natural history of primary lateral sclerosis. Neurology 2006;66:647–53

    Abstract/FREE Full Text
11. 11.↵
    1. Pringle CE,
    2. Hudson AJ,
    3. Munoz DG,
    4. et al

    . Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992;115(pt 2):495–520

    Abstract/FREE Full Text
12. 12.↵
    1. Demougeot C,
    2. Garnier P,
    3. Mossiat C,
    4. et al

    . N-acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001;77:408–15

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Pioro EP,
    2. Antel JP,
    3. Cashman NR,
    4. et al

    . Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933–38

    Abstract/FREE Full Text
14. 14.↵
    1. Block W,
    2. Karitzky J,
    3. Traber F,
    4. et al

    . Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol 1998;55:931–36

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Chan S,
    2. Shungu DC,
    3. Douglas-Akinwande A,
    4. et al

    . Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999;212:763–69

    PubMedWeb of Science
16. 16.↵
    1. Gredal O,
    2. Rosenbaum S,
    3. Topp S,
    4. et al

    . Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997;48:878–81

    Abstract/FREE Full Text
17. 17.↵
    1. Pohl C,
    2. Block W,
    3. Karitzky J,
    4. et al

    . Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001;58:729–35

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Brand A,
    2. Richter-Landsberg C,
    3. Leibfritz D

    . Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–98

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Kalra S,
    2. Hanstock CC,
    3. Martin WR,
    4. et al

    . Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 2006;63:1144–48

    CrossRefPubMed
20. 20.↵
    1. De Stefano N,
    2. Filippi M,
    3. Miller D,
    4. et al

    . Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69:1942–52

    Abstract/FREE Full Text
21. 21.↵
    1. Pioro EP,
    2. Majors AW,
    3. Mitsumoto H,
    4. et al

    . 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999;53:71–79

    Abstract/FREE Full Text
22. 22.↵
    1. Brooks BR,
    2. Miller RG,
    3. Swash M,
    4. et al

    . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–99

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Brugman F,
    2. Wokke JH,
    3. Scheffer H,
    4. et al

    . Spastin mutations in sporadic adult-onset upper motor neuron syndromes. Ann Neurol 2005;58:865–69

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Brugman F,
    2. Scheffer H,
    3. Wokke JH,
    4. et al

    . Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes. Neurology 2008;71:1500–05

    Abstract/FREE Full Text
25. 25.↵
    1. Kent-Braun JA,
    2. Walker CH,
    3. Weiner MW,
    4. et al

    . Functional significance of upper and lower motor neuron impairment in amyotrophic lateral sclerosis. Muscle Nerve 1998;21:762–68

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Cedarbaum JM,
    2. Stambler N,
    3. Malta E,
    4. et al

    . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function—BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13–21

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ellis CM,
    2. Simmons A,
    3. Jones DK,
    4. et al

    . Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999;53:1051–58

    Abstract/FREE Full Text
28. 28.↵
    1. Naidich TP,
    2. Grant JL,
    3. Altman N,
    4. et al

    . The developing cerebral surface: preliminary report on the patterns of sulcal and gyral maturation—anatomy, ultrasound, and magnetic resonance imaging. Neuroimaging Clin N Am 1994;4:201–40

    PubMed
29. 29.↵
    1. Provencher SW

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–79

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Sarchielli P,
    2. Pelliccioli GP,
    3. Tarducci R,
    4. et al

    . Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001;43:189–97

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Czaplinski A,
    2. Yen AA,
    3. Appel SH

    . Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006;253:1428–36

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Cima V,
    2. Logroscino G,
    3. D'Ascenzo C,
    4. et al

    . Epidemiology of ALS in Padova district, Italy, from 1992 to 2005. Eur J Neurol 2009;16:920–24. Epub 2009 Mar 31

    CrossRefPubMed
33. 33.↵
    1. Czaplinski A,
    2. Yen AA,
    3. Simpson EP,
    4. et al

    . Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Arch Neurol 2006;63:1139–43

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Zhai P,
    2. Pagan F,
    3. Statland J,
    4. et al

    . Primary lateral sclerosis: a heterogeneous disorder composed of different subtypes? Neurology 2003;60:1258–65

    Abstract/FREE Full Text
35. 35.↵
    1. Boillee S,
    2. Yamanaka K,
    3. Lobsiger CS,
    4. et al

    . Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389–92

    Abstract/FREE Full Text
36. 36.↵
    1. Cwik VA,
    2. Hanstock CC,
    3. Allen PS,
    4. et al

    . Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 1998;50:72–77

    Abstract/FREE Full Text
37. 37.↵
    1. Ellis CM,
    2. Simmons A,
    3. Andrews C,
    4. et al

    . A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 1998;51:1104–09

    Abstract/FREE Full Text
38. 38.↵
    1. Kaufmann P,
    2. Pullman SL,
    3. Shungu DC,
    4. et al

    . Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004;62:1753–57

    Abstract/FREE Full Text
39. 39.↵
    1. Mitsumoto H,
    2. Ulug AM,
    3. Pullman SL,
    4. et al

    . Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007;68:1402–10

    Abstract/FREE Full Text
40. 40.↵
    1. Rule RR,
    2. Schuff N,
    3. Miller RG,
    4. et al

    . Gray matter perfusion correlates with disease severity in ALS. Neurology 2010;74:821–27

    Abstract/FREE Full Text
41. 41.↵
    1. Miller TM,
    2. Johnston SC

    . Should the Babinski sign be part of the routine neurologic examination? Neurology 2005;65:1165–68

    Abstract/FREE Full Text